New Drug Application for Novel Anti-Insomnia Drug Quviviq® Accepted
Fully Approved! XIANNUOXIN® Becomes the First Oral Anti-COVID-19 Drug Obtaining Regular Approval in China
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
The latest data from the registrational phase 3 clinical study of suvemcitug for platinum-resistant ovarian cancer has been presented as an LBA oral presentation at 2024 ASCO
Phase III Clinical Study of Daridorexant Reached the Primary Endpoint
2024 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 16 Studies for 4 Pipeline Products on 11 Tumor Types
Simcere Zaiming Announces Enrollment of First Patient in GPRC5D-BCMA-CD3 Tri-Specific Antibody SIM0500 Clinical Trial
Positive Results from Phase III Clinical Study of Deunoxavir Marboxil Tablets, an Innovative Anti-influenza Drug Collaborated by Simcere Pharmaceuticals and AnDiCon Biotech
COSELA® received upgraded evidence-based medicine designation in the CSCO Guidelines for Small Cell Lung Cancer
Expanded Access Policy